series-a
Stage
1
Investors
About
BetaGlue Therapeutics develops YntraDose, a Yttrium-90 microsphere interventional radiotherapeutic platform that delivers localized radiation directly into solid tumors, targeting cancers such as pancreatic and liver cancer. The company is clinical-stage and conducting multiple clinical trials for unresectable locally advanced pancreatic cancer.
Explore BetaGlue Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.